Reports Q4 revenue $2.48B, consensus $2.47B. “In 2024, our unwavering focus on innovation and operational excellence delivered another set of strong results,” said David J. Endicott, Alcon’s (ALC) Chief Executive Officer. “This focus will continue into 2025 as we launch a wave of innovation that we expect to deliver long-term value to our customers, shareholders and associates.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Alcon a launches OTC eye drop SYSTANE PRO preservative-free PF
- Positive Outlook for Alcon Amidst New Product Developments and Market Growth Potential
- Is ALC a Buy, Before Earnings?
- Alcon debuts Voyager DSLT for glaucoma and ocular hypertension treatment
- Positive Outlook for Alcon Despite Patent and Exclusivity Challenges, Driven by Product Launches and Legal Protections
Questions or Comments about the article? Write to editor@tipranks.com